CTLA4 and non-small cell lung carcinoma: Late outcomes from randomised Phase III trial in current NSCLC, together with Checkmate-227 and MYSTIC, recommend that excessive TMB won't be as powerful at predicting the patience gain from a mixture of Programmed Death-1 (PD-1) and Cytotoxic T- Lymphocyte-associated Antigen 4 (CTLA-4) inhibitors.